

PLEASE CLICK ON THE PAGE NUMBER TO MOVE TO THE RELEVANT PAGE.

### KEY HIGHLIGHTS

#### Update

#### Sido Muncul (SIDO IJ/HOLD/Rp500/Target: Rp550)

Flattish or slight yoy decline in profit growth in the next few quarters.

Page 2

#### TRADERS' CORNER

Charoen Pokphand Indonesia (CPIN IJ): Technical BUY

Telkom Indonesia (TLKM IJ): Technical BUY

Page 5

### REGIONAL MARKET

Market	Close	+ / -	Chg (%)
MSCI Indonesia	7,310.8	42.7	0.6
MSCI Asia-Ex Japan	620.8	2.3	0.4
KLCI	1,452.7	6.7	0.5
FSSTI	3,073.0	(11.7)	(0.4)
SET	1,380.2	(7.5)	(0.5)
Hang Seng	17,042.9	49.4	0.3
Nikkei	33,486.9	165.7	0.5
Shanghai Comp	3,029.7	8.0	0.3
Dow Jones	35,950.9	520.5	1.4

Source: Bloomberg

### INDONESIA STOCK EXCHANGE

	Level	+ / -	Chg (%)
Index	7,080.7	44.7	0.6
LQ-45	930.0	5.7	0.6
Value (US\$m)	1,625.3	973.4	149.3

### FOREIGN TRADE IN IDX

Net (US\$m)	Buy	Sell	Total (%)
(17.4)	1,032.1	1,049.5	64.0

### TOP TRADING TURNOVER

Company	Price (Rp)	Chg (%)	5-day ADT (Rpb)
Amman Mineral	7,200	(7.4)	1,410.1
Bank Central Asia	8,975	0.8	744.2
Bank Rakyat Indonesia	5,275	(0.5)	705.4
Astra International	5,400	(2.3)	442.4
Telkom Indonesia	3,760	1.1	405.8

### TOP GAINERS

Company	Price (Rp)	Chg (%)	5-day ADT (Rpb)
Siloam International	2,740	19.7	10.8
Indofood CBP	11,550	10.0	60.4
Petrindo Jaya	8,825	10.0	134.0
Indocement TP	10,200	8.5	19.8
Pertamina Geothermal	1,055	5.5	90.1

### TOP LOSERS

Company	Price (Rp)	Chg (%)	5-day ADT (Rpb)
Amman Mineral	7,200	(7.4)	1,410.1
Bumi Resources	102	(5.6)	86.8
Medco Energi	1,155	(4.1)	107.2
Vale Indonesia	4,500	(4.1)	287.6
Smartfren Telecom	51	(3.8)	10.6

\*ADT: Average daily turnover

### COMMODITY TREND

	30 Nov 23 Closing	Chg (%)	
		1-day	1-mth
Forex (Rp/US\$)	15,510	0.7	(2.4)
Crude Oil NYMEX (US\$/bbl)	75.96	(2.4)	(6.2)
Coal Fut Newc (US\$/tonne)	132.15	3.4	n.a.
Nickel 3M LME	17,122	0.0	(5.6)
Tin 3M LME	23,501	0.0	(2.4)
Gold SPOT (US\$/oz)	2,038	0.0	1.9
CPO Fut Msia (MYR/tonne)	3,754	0.5	5.3

Source: Bloomberg, UOB Kay Hian

### COMPANY UPDATE

## Sido Muncul (SIDO IJ)

Flattish Or Slight Yoy Decline In Profit Growth In Next Few Quarters

We expect SIDO's profit growth to be flattish or decline slightly on a yoy basis in the next few quarters. Monthly sales in Oct and Nov 23 point to a potential qoq increase. SIDO indicates that it will spend less in 4Q23 advertising and 4Q23 SGA expense will be lower qoq. As of Aug 23, all its pharmacy products have passed BPOM testing, and there could be a qoq recovery as BPOM (Indonesia's FDA) has granted safety approvals for the products to be sold. Maintain HOLD with a lower target price of Rp550.

### WHAT'S NEW

- Oct and Nov 23 sales improve qoq but still soft yoy.** Sido Muncul (SIDO) stated that its Oct 23 sales improved qoq compared with average monthly sales in 3Q23. Indications for Nov 23 sales point to flat mom sales, implying a potential qoq increase in 4Q23 sales. SIDO also acknowledged that despite the mom improvement, 4Q23 sales is likely to decline yoy due to a significant decline in herbal consumption.
- Less advertising & promotional spending in 4Q23.** In 3Q23, advertising & promotional expenses rose 19.7% yoy and 67.6% qoq. SIDO stated that it decided to increase advertising & promotion in order to maintain market share. Going forward to 4Q23, advertising & promotional expenses are likely to decline qoq as spending will normalise.
- All pharmaceutical products have passed BPOM (Indonesia Food & Drug Administration) testing.** In 9M23, sales of the pharmaceutical division fell 25.6% yoy due to a national review and retest of all children's cough syrups. In 1Q23, 18 of SIDO's products had to be tested but at the end of 1H23, only five products were awaiting re-testing. As of Aug 23, all SIDO's pharmaceutical products have passed BPOM testing. The decline in sales has slowed down the softness in purchasing power has still impacted sales volume, causing a 16.4% yoy decline in sales.
- 4Q23 NPAT should improve qoq but remain soft yoy.** We expect SIDO's 4Q23 NPAT to improve qoq driven by: a) sales recovering qoq, b) lower qoq advertising spending, and c) potential qoq recovery in pharmaceutical sales. However, SIDO agrees with our view that its NPAT is likely to decline yoy or remain flat for the next few quarters.

### KEY FINANCIALS

Year to 31 Dec (Rpb)	2021	2022	2023F	2024F	2025F
Net turnover	4,021	3,866	3,484	3,378	3,525
EBITDA	1,663	1,490	1,284	1,309	1,312
Operating profit	1,577	1,393	1,176	1,193	1,220
Net profit (rep./act.)	1,261	1,104	934	935	957
Net profit (adj.)	1,261	1,104	934	935	957
EPS (Rp)	42.0	36.8	31.1	31.2	31.9
PE (x)	11.9	13.6	16.1	16.0	15.7
P/B (x)	4.3	4.3	3.9	3.7	3.5
EV/EBITDA (x)	8.2	9.1	10.6	10.4	10.4
Dividend yield (%)	6.8	5.9	5.0	5.0	5.2
Net margin (%)	31.4	28.6	26.8	27.7	27.1
Net debt/(cash) to equity (%)	(31.2)	(26.3)	(35.4)	(37.7)	(38.2)
ROE (%)	37.7	31.7	25.2	23.5	23.0
Consensus net profit	-	-	915	1,014	1,104
UOBKH/Consensus (x)	-	-	1.02	0.92	0.87

Source: Sido Muncul, Bloomberg, UOB Kay Hian

### HOLD

(Maintained)

Share Price	Rp500
Target Price	Rp550
Upside	+10.0%
(Previous TP)	Rp680

### COMPANY DESCRIPTION

The largest herbal medicine (jamu) and energy drink producer in Indonesia

### STOCK DATA

GICS sector	Consumer Staples
Bloomberg ticker:	SIDO IJ
Shares issued (m):	30,000.0
Market cap (Rpb):	15,000.0
Market cap (US\$m):	967.1
3-mth avg daily t'over (US\$m):	1.1


### Price Performance (%)

52-week high/low	Rp910/Rp486			
<b>1mth</b>	<b>3mth</b>	<b>6mth</b>	<b>1yr</b>	<b>YTD</b>
(2.0)	(19.4)	(31.0)	(36.3)	(33.8)

### Major Shareholders

	%
Hotel Candi Baru	81.0
FY23 NAV/Share (Rp)	130
FY23 Net Cash/Share (Rp)	46

### PRICE CHART



Source: Bloomberg

### ANALYST(S)

**Stevanus Juanda**  
 +6221 2993 3845  
 stevanusjuanda@uobkayhian.com

### STOCK IMPACT

- **Softness in purchasing power and currency depreciation in Nigeria affected F&B business.** SIDO attributed the weakness in sales of its F&B segment to weakness in purchasing power domestically and weakness in export sales to Nigeria. Nigeria has suffered a significant currency depreciation that has caused severe weakness in purchasing power; SIO currently is reducing exposure to Nigeria.
- **Herbal:** 3Q23 herbal sales declined by 32.3% yoy and gross profit declined by 32.1% yoy. 9M23 sales declined by 12.1% yoy and gross profit declined by 11.7% yoy. Gross margin was stable in 3Q23 and 9M23, improving slightly by 23bp and 34bp yoy.
- **Food & beverage:** 3Q23 F&B sales declined 24.4% yoy and gross profit declined by 5% yoy. 3Q23 gross margin expanded by 699bp. 9M23 sales declined by 2.6% yoy but gross profit rose 5.6% yoy. 9M23 gross margin expanded by 251bp yoy.
- **Pharmacy:** 3Q23 sales declined 16.4% yoy and gross profit declined by 21.6% yoy. 3Q23 gross margin contracted by 238bp. 9M23 sales declined by 25.6% yoy as BPOM reviewed SIDO's cough medicine and gross profit declined 37.1% yoy. 9M23 gross margin dropped by 606bp.

### 9M23 AND 3Q23 SEGMENTAL ANALYSIS

	Food & Beverage				Growth (%)	Food & Beverage				Margin (%)	Food & Beverage			
	Herbal	Beverage	Pharmacy	Total		Herbal	Beverage	Pharmacy	Total		Herbal	Beverage	Pharmacy	Total
<b>9M23</b>														
Sales	1,455.5	820.4	85.4	2,361.3	Sales	-12.1%	-2.6%	-25.6%	-9.7%	Sales	100.0	100.0	100.0	100.0
COGS	(479.9)	(556.2)	(57.2)	(1,093.4)	COGS	-13.0%	-6.1%	-18.2%	-9.9%	COGS	(33.0)	(67.8)	(67.0)	(46.3)
Gross Profit	975.6	264.2	28.2	1,267.9	Gross Profit	-11.7%	5.6%	-37.1%	-9.4%	Gross Profit	67.0	32.2	33.0	53.7
<b>3Q23</b>														
Sales	452.0	225.2	30.3	707.5	Sales	-32.3%	-24.4%	-16.4%	-29.4%	Sales	100.0	100.0	100.0	100.0
COGS	(149.4)	(148.2)	(19.5)	(317.1)	COGS	-32.8%	-31.6%	-13.2%	-31.3%	COGS	(33.1)	(65.8)	(64.4)	(44.8)
Gross Profit	302.6	77.0	10.8	390.4	Gross Profit	-32.1%	-5.0%	-21.6%	-27.7%	Gross Profit	66.9	34.2	35.6	55.2

Source: SIDO UOB Kay Hian

### EARNINGS REVISION/RISK

- **Lowering 2023/2024 net income forecasts by 4.3%/11.1%.** Considering the weak 3Q23 results, we lower our 2023/24 NPAT forecasts by 4.3%/11.1% respectively. Our 2024F NPAT forecast is 7.7% below that of consensus.

### NEW, ORIGINAL AND CONSENSUS FORECASTS

	New		Original		Difference (%)		Street		Difference (%)	
	2023F	2024F	2023F	2024F	2023F	2024F	2023F	2024F	2023F	2024F
Sales	3,484	3,378	3,653	3,712	-4.6%	-9.0%	3,458	3,682	0.8%	-8.3%
Gross Profit	1,934	1,824	2,030	2,026	-4.7%	-9.9%	1,898	2,041	1.9%	-10.6%
Op Profit	1,176	1,193	1,271	1,346	-7.5%	-11.3%	1,147	1,269	2.5%	-6.0%
Net Income	934	935	976	1,052	-4.3%	-11.1%	915	1,014	2.0%	-7.7%

	New		Original		Difference (%)		Street		Difference (%)	
	2023F	2024F	2023F	2024F	2023F	2024F	2023F	2024F	2023F	2024F
Gross Profit	55.5	54.0	55.6	54.6	-	5	54.9	55.4	63	- 140
Op Profit	33.7	35.3	34.8	36.3	- 104	- 93	33.2	34.5	56	86
Net Income	26.8	27.7	26.7	28.3	8	- 64	26.5	27.5	33	17

Source: SIDO UOB Kay Hian

### VALUATION/RECOMMENDATION


- **Maintain HOLD and lower target price to Rp550.** Revisiting our model has resulted in a lowering of target price from Rp680 to Rp550. Our target price is derived by using a -1SD historical 5-year average PE (17.6x) applied to 2024F EPS. We use -1SD PE because we are expecting weak NPAT growth in the next few quarters.

### 9M23 AND 3Q23 SGA EXPENSE

	9M23	9M22	YoY(%)	3Q23	3Q22	YoY(%)	QoQ(%)	2023	1Q23
Sales	2,361.3	2,613.8	-9.7%	707.5	1,001.7	-29.4%	-5.2%	746.5	907.3
SGA	530.3	517.9	2.4%	225.1	197.8	13.8%	22.2%	184.3	120.9
	9M23	9M22	YoY(%)	3Q23	3Q22	YoY(%)	QoQ(%)	2023	1Q23
Adv & Promotion	227.0	218.8	3.7%	120.6	100.7	19.7%	67.6%	71.9	34.5
Salary & Allowance	68.6	61.2	12.1%	22.4	20.4	9.7%	-18.6%	27.5	18.7
Freight Out	31.6	35.7	-11.4%	10.1	12.3	-17.8%	1.8%	9.9	11.6
Donation	4.8	4.4	8.8%	1.2	0.6	96.0%	-16.4%	1.4	2.1
Travelling	4.6	2.6	77.5%	1.7	1.2	41.7%	5.7%	1.6	1.2
Rent	2.3	2.2	4.3%	0.7	0.7	9.4%	-14.8%	0.9	0.7
Depreciation	1.0	1.0	-2.6%	0.3	0.3	-3.6%	-0.9%	0.3	0.3
Others	26.5	20.1	31.6%	11.4	9.5	20.1%	48.5%	7.7	7.4
<b>Total Selling Exp</b>	<b>366.3</b>	<b>346.0</b>	<b>5.9%</b>	<b>168.4</b>	<b>145.8</b>	<b>15.5%</b>	<b>38.9%</b>	<b>121.3</b>	<b>76.6</b>
	9M23	9M22	YoY(%)	3Q23	3Q22	YoY(%)	QoQ(%)	2023	1Q23
Salary & Allowance	116.3	122.8	-5.3%	39.8	38.2	4.1%	-12.6%	45.6	30.9
Post Employment Benefit	13.2	17.2	-23.0%	4.4	5.4	-17.7%	0.0%	4.4	4.4
Depreciation	5.7	3.9	47.4%	2.5	1.3	90.7%	25.0%	2.0	1.3
Professional Fees	2.1	3.9	-46.5%	0.8	2.1	-62.8%	-31.3%	1.1	0.2
Others	26.7	24.1	10.6%	9.2	5.0	83.0%	-6.6%	9.9	7.5
<b>Total Gen &amp; Admin</b>	<b>164.0</b>	<b>171.9</b>	<b>-4.6%</b>	<b>56.7</b>	<b>52.0</b>	<b>9.0%</b>	<b>-10.0%</b>	<b>63.0</b>	<b>44.3</b>

Source: SIDO UOB Kay Hian

### PE BAND



Source: SIDO UOB Kay Hian

### PROFIT & LOSS

Year to 31 Dec (Rpb)	2022	2023F	2024F	2025F
Net turnover	3,866	3,484	3,378	3,525
EBITDA	1,490	1,284	1,309	1,312
Deprec. & amort.	97	109	116	92
EBIT	1,393	1,176	1,193	1,220
Total other non-operating income	0.0	0.0	0.0	0.0
Net interest income/(expense)	27	26	14	15
<b>Pre-tax profit</b>	<b>1,419</b>	<b>1,202</b>	<b>1,207</b>	<b>1,234</b>
Tax	(315)	(268)	(272)	(278)
Minorities	0.0	0.0	0.0	0.0
<b>Net profit</b>	<b>1,104</b>	<b>934</b>	<b>935</b>	<b>957</b>
Net profit (adj.)	1,104	934	935	957

### BALANCE SHEET

Year to 31 Dec (Rpb)	2022	2023F	2024F	2025F
Fixed assets	1,611	1,761	1,784	1,841
Other LT assets	276	291	306	322
Cash/ST investment	923	1,379	1,536	1,626
Other current assets	1,271	894	878	921
<b>Total assets</b>	<b>4,081</b>	<b>4,325</b>	<b>4,504</b>	<b>4,710</b>
ST debt	0.0	0.0	0.0	0.0
Other current liabilities	541	395	393	414
LT debt	0.0	0.0	0.0	0.0
Other LT liabilities	35	36	38	39
Shareholders' equity	3,505	3,893	4,073	4,257
Minority interest	0.0	0.0	0.0	0.0
<b>Total liabilities &amp; equity</b>	<b>4,081</b>	<b>4,325</b>	<b>4,504</b>	<b>4,710</b>

### CASH FLOW

Year to 31 Dec (Rpb)	2022	2023F	2024F	2025F
<b>Operating</b>	<b>1,107</b>	<b>1,352</b>	<b>1,064</b>	<b>1,025</b>
Pre-tax profit	1,419	1,202	1,207	1,234
Tax	(315)	(268)	(272)	(278)
Deprec. & amort.	97	109	116	92
Working capital changes	(90)	402	15	(28)
Non-cash items	(24)	(163)	(1.8)	4.6
Other operating cashflows	20	71	0.3	(0.5)
<b>Investing</b>	<b>(180)</b>	<b>(142)</b>	<b>(152)</b>	<b>(162)</b>
Capex (growth)	(116)	(130)	(139)	(149)
Investments	0.0	0.0	0.0	0.0
Proceeds from sale of assets	(63)	(4.0)	(4.2)	(4.4)
Others	(1.2)	(7.8)	(8.2)	(8.6)
<b>Financing</b>	<b>(1,088)</b>	<b>(754)</b>	<b>(755)</b>	<b>(773)</b>
Dividend payments	(1,086)	(754)	(755)	(773)
Issue of shares	4.1	0.0	0.0	0.0
Proceeds from borrowings	0.0	0.0	0.0	0.0
Loan repayment	0.0	0.0	0.0	0.0
Others/interest paid	(6.3)	0.0	0.0	0.0
<b>Net cash inflow (outflow)</b>	<b>(161)</b>	<b>456</b>	<b>157</b>	<b>90</b>
<b>Beginning cash &amp; cash equivalent</b>	<b>1,082</b>	<b>923</b>	<b>1,379</b>	<b>1,536</b>
Changes due to forex impact	1.5	0.0	0.0	0.0
<b>Ending cash &amp; cash equivalent</b>	<b>923</b>	<b>1,379</b>	<b>1,536</b>	<b>1,626</b>

### KEY METRICS

Year to 31 Dec (%)	2022	2023F	2024F	2025F
<b>Profitability</b>				
EBITDA margin	38.5	36.9	38.7	37.2
Pre-tax margin	36.7	34.5	35.7	35.0
Net margin	28.6	26.8	27.7	27.1
ROA	27.1	22.2	21.2	20.8
ROE	31.7	25.2	23.5	23.0
<b>Growth</b>				
Turnover	(3.9)	(9.9)	(3.1)	4.4
EBITDA	(10.4)	(13.8)	1.9	0.2
Pre-tax profit	(12.0)	(15.4)	0.4	2.3
Net profit	(12.4)	(15.5)	0.2	2.3
Net profit (adj.)	(12.4)	(15.5)	0.2	2.3
EPS	(12.4)	(15.5)	0.2	2.3
<b>Leverage</b>				
Debt to total capital	0.0	0.0	0.0	0.0
Debt to equity	0.0	0.0	0.0	0.0
Net debt/(cash) to equity	(26.3)	(35.4)	(37.7)	(38.2)

### TRADERS' CORNER



### Charoen Pokphand Indonesia (CPIN IJ)

Technical BUY with 8% potential return

Resistance: Rp5,400, Rp5,600

Support: Rp5,000, Rp4,880

Stop-loss: Rp4,950

Share price closed slightly higher and formed a neutral candlestick. Price rebounded from its support area hence it could trigger more rebounds and challenge the resistances at Rp5,400 and Rp5,600. Technical indicator RSI is sloping upwards and moving away from its oversold zone, while the MACD is on bearish crossover. Buy at Rp5,125 and take profit at Rp5,600.

Approximate timeframe: 2-4 weeks.



### Telkom Indonesia (TLKM IJ)

Technical BUY with 5% potential return

Resistance: Rp3,880, Rp3,940

Support: Rp3,700, Rp3,670

Stop-loss: Rp3,700

Share price closed higher and formed a neutral candlestick. Momentum is looking more positive hence we expect more bullish pressure to take place and challenge the resistances at Rp3,880 and Rp3,940. Technical indicator RSI is sloping upwards and above its centre line, while the MACD is on bullish crossover. Buy at Rp3,760 and take profit at Rp3,940.

Approximate timeframe: 2-4 weeks.

Our institutional research has a fundamental BUY and target price of Rp4,700.

#### ANALYST(S)

**Maskun Ramli, CFTE**  
 +6221 2993 3915  
 maskunramli@uobkayhian.com

## Disclosures/Disclaimers

This report is prepared by PT UOB Kay Hian Sekuritas ("PT UOBKH"), a licensed broker dealer registered in the Republic of Indonesia and a member of the Indonesia Stock Exchange ("IDX")

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

**This report is prepared for general circulation.** It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of PT UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as PT UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject PT UOBKH and its associates and its officers, employees and representatives to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by PT UOBKH to be reliable. However, PT UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and PT UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information PT UOBKH and its associate may have issued other reports expressing views different from the Information and all views expressed in all reports of PT UOBKH and its connected persons are subject to change without notice. PT UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) PT UOBKH, its associates and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) PT UOBKH, its associate and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of PT UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) PT UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

**IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report is prepared by PT UOBKH, a company authorized, as noted above, to engage in securities activities in Indonesia. PT UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by PT UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from PT UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through PT UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



## Analyst Certification/Regulation AC

Each research analyst of PT UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of PT UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including PT UOBKH total revenues, a portion of which are generated from PT UOBKH business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, PT UOB Kay Hian Sekuritas. All rights reserved.

<http://research.uobkayhian.com>